When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors?
- PMID: 37510695
- PMCID: PMC10380401
- DOI: 10.3390/jcm12144581
When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors?
Abstract
Pancreatic neuroendocrine neoplasms (PanNENs) are rare and heterogeneous diseases that account for less than 2% of all cases of pancreatic cancer and only 30% of digestive neuroendocrine neoplasia, even if their incidence and prevalence continue to rise globally [...].
Conflict of interest statement
Alberto Larghi received educational fee from Taewoong.
References
-
- Panzuto F., Merola E., Pavel M.E., Rinke A., Kump P., Partelli S., Rinzivillo M., Rodriguez-Laval V., Pape U.F., Lipp R., et al. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist. 2017;22:409–415. doi: 10.1634/theoncologist.2016-0351. - DOI - PMC - PubMed
-
- Jilesen A.P.J., van Eijck C.H.J., Hof K.H.I., van Dieren S., Gouma D.J., van Dijkum E.J.M.N. Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review. World J. Surg. 2015;40:729–748. doi: 10.1007/s00268-015-3328-6. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources